Corona Remedies Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹353Cr
- +20.1% YoY
- +3.2% QoQ
- Net profit
- ₹45Cr
- +45.2% YoY
- +9.8% QoQ
- Margin
- 18%
- 0 pp YoY
- −6 pp QoQ
Guidance rank: #51 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27.
From Corona Remedies Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches.
- CORONA Remedies expects to outperform the market volume growth by about 3x to 4x through added medical representatives and restructuring of divisions, including launching new products like Wokadine.
- Committed to 15% organic revenue growth domestically and 25% growth in the acquired portfolio, targeting 20%+ PAT growth in FY27.
2 more points from Corona Remedies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Corona Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Expansion of manufacturing capabilities with the addition of a new 600-kg production line.
- Commissioning of a dedicated hormone manufacturing plant expected to be operational in Q1 or Q2 of FY27.
- Receipt of EAEU GMP certification enabling expansion into key Eurasian markets (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan).
- These investments aim to strengthen manufacturing backbone, improve scalability, and support growth in domestic and international business.
2 more points from Corona Remedies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Corona Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Corona Remedies Ltd said on order book & pipeline — free account, 30 seconds.
Corona Remedies Ltd — Quarterly revenue & net profit
Corona Remedies Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 353 | 294 | +20.1% | 342 | +3.2% |
| Operating profit (EBITDA) | 62 | 54 | +14.8% | 83 | -25.3% |
| Operating margin | 18% | 18% | 0 pp | 24% | -6 pp |
| Profit before tax | 54 | 43 | +25.6% | 55 | -1.8% |
| Net profit (PAT) | 45 | 31 | +45.2% | 41 | +9.8% |
| EPS (₹) | 7.37 | 5.12 | +43.9% | 6.74 | +9.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹441 Cr, net profit ₹60 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Corona Remedies's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Corona Remedies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Corona Remedies Ltd Q4 FY26 results?
Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27.
What is Corona Remedies Ltd share price analysis?
Corona Remedies Ltd currently shows a neutral. The stock trades at a P/E of 60.6 with a market cap of ₹12,823 Cr. Investors should review the full earnings analysis for detailed insights.
Is Corona Remedies Ltd planning capital expenditure?
Expansion of manufacturing capabilities with the addition of a new 600-kg production line.
Keep Corona Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
